Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
—
−0.2329USD
−101.98 MUSD
69.52 MUSD
285.53 M
About VENUS MEDTECH HANGZHOU INC.
Sector
Industry
CEO
Hou-Sen Lim
Website
Headquarters
Wanchai
Employees (FY)
865
Founded
2009
ISIN
CNE100003PJ8
FIGI
BBG00Z1W7XK8
Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. It engages in the research and development of cardiac intervention system for heart diseases. The company offers pre-implanted invasive heart valve systems such as transcatheter artery and pulmonary artery valve systems, and delivery catheter systems. The company was founded on July 3, 2009 and is headquartered in Hangzhou, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of VMTHF is 0.0108 USD — it has decreased by 98.32% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange VENUS MEDTECH HANGZHOU INC. stocks are traded under the ticker VMTHF.
VENUS MEDTECH HANGZHOU INC. is going to release the next earnings report on Aug 29, 2024. Keep track of upcoming events with our Earnings Calendar.
VMTHF stock is 5.85 K% volatile and has beta coefficient of 2.04. Check out the list of the most volatile stocks — is VENUS MEDTECH HANGZHOU INC. there?
VMTHF earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.09 USD resulting in a −19.40% surprise. The estimated earnings for the next quarter are −0.08 USD per share. See more details about VENUS MEDTECH HANGZHOU INC. earnings.
VENUS MEDTECH HANGZHOU INC. revenue for the last quarter amounts to 35.24 M USD despite the estimated figure of 34.87 M USD. In the next quarter revenue is expected to reach 36.59 M USD.
Yes, you can track VENUS MEDTECH HANGZHOU INC. financials in yearly and quarterly reports right on TradingView.
VMTHF net income for the last quarter is −51.27 M USD, while the quarter before that showed −50.52 M USD of net income which accounts for −1.48% change. Track more VENUS MEDTECH HANGZHOU INC. financial stats to get the full picture.
Today VENUS MEDTECH HANGZHOU INC. has the market capitalization of 314.14 M, it has decreased by 0.05% over the last week.
No, VMTHF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VMTHF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VENUS MEDTECH HANGZHOU INC. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 865.00 employees. See our rating of the largest employees — is VENUS MEDTECH HANGZHOU INC. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VENUS MEDTECH HANGZHOU INC. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VENUS MEDTECH HANGZHOU INC. stock shows the buy signal. See more of VENUS MEDTECH HANGZHOU INC. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on VENUS MEDTECH HANGZHOU INC. future price: according to them, VMTHF price has a max estimate of 0.77 USD and a min estimate of 0.77 USD. Read a more detailed VENUS MEDTECH HANGZHOU INC. forecast: see what analysts think of VENUS MEDTECH HANGZHOU INC. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VENUS MEDTECH HANGZHOU INC. EBITDA is −66.81 M USD, and current EBITDA margin is −95.60%. See more stats in VENUS MEDTECH HANGZHOU INC. financial statements.